10900 WILSHIRE BLVD, LOS ANGELES, CA
Director Elections and Crowe LLP Appointment Ratified at Annual Meeting
Reports First Quarter 2026 Financial Results
Increases Share Repurchase Program to $20 Million
Investor Presentation
To Streamline and Focus its Operations with the Sale of Reference Standards Business to LGC in All-Cash Transaction
Acquires Core Nicotinamide Riboside (NR) Patent Portfolio from Queen’s University Belfast
Announces $10 Million Share Repurchase Program
Reports Third Quarter 2025 Financial Results and Reaffirms Increased Full Year Outlook
Q1
FY 2025
Q3
Q2
FY 2024
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(3)
Prospectus filed pursuant to Rule 424(b)(5)
Definitive Proxy Statement
Additional Proxy Materials
Statement of Changes in Beneficial Ownership
Correspondence
Submission Upload
Confidential Treatment Order